Fortress Biotech (FBIO) Stock Analysis & Winston Score

Fortress Biotech is a pharmaceutical company that develops and sells medicines. It focuses on specialty drugs, meaning treatments for diseases that are harder to treat and have fewer options available. The company owns or has stakes in multiple smaller drug companies, acting almost like a parent company that helps build new biotech businesses under one roof. Fortress makes money by selling approved drugs and by collecting royalties and fees from its partner companies when those companies hit certain milestones or generate revenue. It operates mainly in the United States and has a portfolio of both commercial products and drugs still in clinical trials. The company is small, with a market cap around $100 million, and it carries significant financial risk — its operating margin is deeply negative, meaning it spends far more than it earns, which is common for early-stage biotech firms. The key risk is whether its pipeline drugs can reach approval and generate enough revenue to cover its heavy spending.